STOCK TITAN

908 Devices Inc. - MASS STOCK NEWS

Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.

908 Devices Inc. (Symbol: MASS) is revolutionizing the field of chemical analysis by making mass spectrometry accessible and user-friendly. Headquartered in Boston, the company specializes in developing point-of-need chemical analysis devices that range from rugged handheld tools to compact and efficient analyzers. These devices, based on advanced High Pressure Mass Spectrometry (HPMS), are designed to offer quick, actionable insights into unknown and invisible materials.

908 Devices serves a variety of industries, including safety and security, oil & gas, life sciences, and other applied markets. Their products are purpose-built and user-centric, catering to the specific needs of each market. The company is committed to providing innovative solutions that address critical problems in sectors such as life sciences research, bioprocessing, industrial biotech, and forensics.

In terms of financial performance, 908 Devices derives the bulk of its revenue from the United States, although it also has a significant presence in Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. Recent achievements include the development of a suite of advanced Mass Spec devices that are compact yet highly effective. These devices are designed to be used at the point of need, offering rapid and reliable chemical analysis that is crucial for various applications.

One of the key areas of focus for 908 Devices is to democratize chemical analysis, making it more accessible and easier to use for a broader range of users. By doing so, the company aims to accelerate the pace of innovation and discovery in multiple fields. Their products are not only technologically advanced but also user-friendly, ensuring that even non-experts can operate them effectively.

In the latest news, 908 Devices continues to push the boundaries of what is possible with mass spectrometry. They have recently announced several new partnerships and product launches that aim to further enhance their capabilities and market reach. These developments highlight the company's commitment to staying at the forefront of the chemical analysis industry.

Rhea-AI Summary

908 Devices (Nasdaq: MASS), a leading developer of handheld and desktop devices for chemical and biochemical analysis, announced its participation in two upcoming investor conferences. The company will host a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas, on May 29 at 8:00 a.m. CT. Additionally, 908 Devices will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois, on June 4 at 10:40 a.m. CT. Live and archived webcasts of these events will be available on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
-
Rhea-AI Summary

908 Devices Inc. (Nasdaq: MASS) reported 5% revenue growth in Q1 2024 compared to Q1 2023, reaching $10 million. Handheld revenue increased by 20%, while desktop revenue decreased by 18%. Recurring revenue was $4.5 million, with 45% of total revenue being recurring. The company acquired RedWave Technology, published its inaugural ESG report, and ended the quarter with $134.2 million in cash and no debt. Gross profit was $5.0 million, net loss was $10.9 million, and EPS was $0.33. Operating expenses were $17.7 million. The company expects 2024 revenue to be $63.0-65.0 million, a 25-29% increase over 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
Rhea-AI Summary

908 Devices Inc. (Nasdaq: MASS) has acquired RedWave Technology, enhancing its forensic product offerings through the addition of optical spectroscopy technology. This move expands 908 Devices' handheld and desktop mass spec devices for chemical and biochemical analysis. The acquisition enables the company to offer a wider range of analytical devices for forensic workflows, including rapid chemical identification of bulk materials using FTIR spectroscopy. RedWave's innovative products are expected to boost 908 Devices' revenue and strategic objectives, with a purchase consideration of $53.5 million, including cash and common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) will report its first quarter 2024 financial results on April 30, 2024. The company specializes in handheld and desktop devices for chemical and biochemical analysis. The conference call will be webcasted at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time, with live audio available on their website. The webcast will be archived for replay within 24 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences earnings
-
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) announces international adoption of MX908 for trace chemical detection and identification, with contracts from DrugDetect EU and NATO Support and Procurement Agency. MX908 deployed in military and correctional settings to detect drugs like cocaine, heroin, and methamphetamine. Operational validation shows effectiveness in identifying trace drug samples. NSPA contract streamlines procurement for NATO member states and allies. MX908 used for CBRNE applications in various environmental conditions. CEO Kevin J. Knopp highlights the versatility and life-saving capabilities of the technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
Rhea-AI Summary
908 Devices Inc. (MASS) reported a 23% revenue increase in Q4 2023 driven by 57% growth in handheld revenue. The company saw a 28% growth in handheld revenue for the full year 2023. Despite near-term challenges in life science industries, 908 Devices launched two desktop devices. The company ended 2023 with $145.7 million in cash and expanded its global presence. Collaboration with Cellares was announced for large-scale cell therapy manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
Rhea-AI Summary
908 Devices Inc. and Cellares announce a collaboration to integrate in-line monitoring of key cell culture parameters into Cellares' Cell Shuttle system. The partnership aims to enhance efficiency, safety, and cost-effectiveness in large-scale cell therapy manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Summary
908 Devices Inc. (MASS) will participate in investor conferences including Cowen 44th Annual Healthcare Conference and KeyBanc Life Sciences & MedTech Forum. Interested parties can access live and archived webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
conferences
-
Rhea-AI Summary
908 Devices Inc. (MASS) will announce Q4 and full-year 2023 financial results on March 5, 2024, with a webcast conference call. The live audio will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences earnings
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) broadens the reach of trace detection and identification at the point of need through the addition of a weatherproof, digital communications port to its handheld MX908 device. This allows companies to integrate the device into their systems for enhanced safety. The recent collaboration with RADēCO, Inc. and DualDraw represents the first adoption for MX908 integrated systems, increasing accessibility to the company's proprietary mass spectrometry technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.12%
Tags
none

FAQ

What is the current stock price of 908 Devices (MASS)?

The current stock price of 908 Devices (MASS) is $2.06 as of December 20, 2024.

What is the market cap of 908 Devices (MASS)?

The market cap of 908 Devices (MASS) is approximately 66.9M.

What does 908 Devices Inc. specialize in?

908 Devices specializes in developing point-of-need chemical analysis devices based on mass spectrometry.

Where is 908 Devices Inc. headquartered?

908 Devices Inc. is headquartered in Boston, Massachusetts.

What industries does 908 Devices serve?

908 Devices serves industries including safety and security, oil & gas, life sciences, and other applied markets.

What technology is the foundation of 908 Devices' products?

Their products are based on High Pressure Mass Spectrometry (HPMS).

What regions contribute to 908 Devices' revenue?

The company derives most of its revenue from the United States and also has significant presence in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.

What recent achievements has 908 Devices announced?

The company has announced new partnerships and product launches aimed at enhancing their capabilities and market reach.

How does 908 Devices aim to democratize chemical analysis?

908 Devices aims to make chemical analysis more accessible and user-friendly, accelerating innovation and discovery in various fields.

What are Mass Spec devices used for?

Mass Spec devices are used to analyze unknown and invisible materials, providing quick and actionable insights.

Are 908 Devices' products user-friendly?

Yes, their products are designed to be user-friendly, ensuring even non-experts can operate them effectively.

How does 908 Devices contribute to life sciences research?

Their Mass Spec devices provide quick and reliable chemical analysis, critical for life sciences research and bioprocessing.

908 Devices Inc.

Nasdaq:MASS

MASS Rankings

MASS Stock Data

66.86M
32.02M
7.6%
69.75%
3.96%
Medical Devices
Measuring & Controlling Devices, Nec
Link
United States of America
BOSTON